A Stanford Medicine study observed the apparent curing of diabetes in mice following transplantation of insulin-secreting pancreatic islet cells. Researchers say the animals’ immune systems accepted the donated cells prior to transplantation. This occurs through a three-pronged process they say they could easily replicate in humans. The mice did not need immune-suppressing treatments after the […]
Oramed inks deal to commercialize oral insulin in the Republic of Korea
Oramed Pharmaceuticals (Nasdaq:ORMP) announced today that it entered into a distribution agreement for its oral insulin candidate in the Republic of Korea. The New York-based developer of oral drug delivery platforms entered into an exclusive commercial distribution agreement with Medicox. The agreement covers the distribution of ORMD-0801 in the Republic of Korea (formerly South Korea). […]
Study supports Tandem t:slim X2 insulin pump for type 2 diabetes
Tandem Diabetes Care (Nasdaq:TNDM) announced that a study of adults with type 2 diabetes supported its automated insulin delivery system. The study evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology. Patients achieved improvement in all clinical endpoints with the technology, which currently does not hold approval for type […]
Insulet warns of battery issues with some Omnipod Dash PDM devices
Insulet (Nasdaq:PODD) recently issued a voluntary global safety notice to warn of battery problems with its Omnipod Dash system. The Omnipod Dash is Insulet’s previous-generation insulin pump. The company since launched its FDA-cleared and CE-marked Omnipod 5 next-generation automated insulin delivery system. Insulet’s notice went out to current and past users of the Omnipod Dash […]
Insulet stock rises on Street-beating Q3, raised sales guidance
Insulet (Nasdaq:PODD) shares ticked up after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of PODD rose 8.1% at $276 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 3.8%. The Acton, […]
Sernova to enroll second cohort in trial of Cell Pouch System for type 1 diabetes
Sernova announced today that it received approval for a protocol amendment in the trial of its Cell Pouch System for treating type 1 diabetes. London, Ontario-based Sernova designed its proprietary Cell Pouch System as an implantable and scalable medical device. It forms a natural environment in the body for the long-term survival and function of […]
Ascensia, Senseonics partner with Nurse Practitioner Group on CGM insertion options
Senseonics (NYSE:SENS) and Ascensia Diabetes Care launched a collaboration with the Nurse Practitioner Group (NPG) today. NPG offers multidisciplinary health services and medical staffing solutions. The collaboration aims to broaden access to the Eversense E3 continuous glucose monitor (CGM) system. Senseonics developed Eversense E3 and Ascensia distributes the system as the company’s partner. The collaboration […]
Glaukos beats The Street in Q3
Glaukos (NYSE:GKOS) shares hardly shifted on third-quarter results that came in ahead of the consensus forecast. The Aliso Viejo, California-based ophthalmic implant maker posted losses of $27.6 million in the quarter. That amounts to 58¢ per share on sales of $71.3 million for the three months ended Sept. 30, 2022. Glaukos registered a deep bottom-line […]
Tandem stock dives on Q3 misses, reduced guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares took a big hit after hours on third-quarter results that missed the consensus forecast. Shares of TNDM. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.3%. The San Diego-based company posted losses of nearly $49 million for the […]
Fractyl Health forms task force to understand root causes of type 2 diabetes
Fractyl Health announced today that it created the Erase T2D task force to research type 2 diabetes in the hopes of “erasing” the condition. The academic-industry scientific partnership aims to advance research on the role of the gut in metabolic disease. This, in turn, could catalyze future discoveries on understanding and erasing type 2 diabetes. […]
